Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Clinical experience and safety of venetoclax in the treatment of patients with chronic lymphocytic leukemia in second and subsequent lines of therapy: Real-world data fron hemato-oncology centers  of slovakia

View Full Paper
Ask AI
Bookmark
Share

Authors

JCJuraj ChudejEFEmília FlochováĽVĽubica Váleková

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows venetoclax improves outcomes in CLL, suggesting it benefits patients after ibrutinib.

Key Points

  • Evaluate the efficacy and safety of venetoclax in patients with chronic lymphocytic leukemia in second-line or subsequent therapy.
  • Retrospective analysis of 98 patients with CLL in Slovakia
  • Venetoclax administered as monotherapy or with rituximab
  • Evaluated response and adverse events based on established criteria
  • Analyzed data using descriptive statistics and Kaplan-Meier for survival rates
  • Overall response rate of 67% with venetoclax
  • Median progression-free survival was 46 months
  • Patients previously treated with ibrutinib had worse outcomes
  • 64% experienced hematologic adverse events, 42% non-hematologic adverse events

Cite This Study

Chudej et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d218https://doi.org/10.1182/blood-2025-7424
View Full Paper
Ask AI
Bookmark
Share